Zydus aims to develop drug for fatty liver disease

Making presentation on Lipaglyn at AACE this month

Ahmedabad-based pharma major Zydus Cadila, which is planning to develop a medicine for patients suffering from fatty liver disease, is making a presentation on its novel drug Lipaglyn at the American Association of Clinical Endocrinologists (AACE) 24th Annual Scientific and Clinical Congress to be held this month.

At the conference scheduled to be held between May 13 to 17 at Nashville, Tennessee, USA, the company would be presenting an abstract titled '9-month safety and efficacy of Saroglitazar in Diabetic Dyslipidemia'.

Pankaj R. Patel, chairman and managing director, Zydus Group said, "The robust scientific data on safety and efficacy of Saroglitazar in Diabetic Dyslipidemia accepted for presentation at this year's AACE meeting reflects our continued commitment to patients suffering from diabetes and dyslipidemia. Because of its unique mechanism of action, we see huge potential of Saroglitazar in treating Non-alcoholic Steatohepatitis (NASH) and going further we will develop this important therapeutic for millions of patients suffering from fatty liver disease".

 

Lipaglyn (Saroglitazar) was launched in September 2013 in India, for treating Hypertriglyceridemia and Diabetic Dyslipidemia in Patients with Type 2 Diabetes not controlled by statins. Since then, more than 80,000 patients are availing this drug with a prescriber base over 3500 diabetologists, cardiologists and physicians, a company statement here claimed. Zydus group employs over 1200 scientists engaged in R&D.